PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1482466
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1482466
The global canine influenza vaccine market is estimated to be valued at USD 1,805.7 Mn in 2024, and is expected to reach USD 2,562.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.1% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | US$ 1,805.7 Mn |
Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
Forecast Period 2024 to 2031 CAGR: | 5.10% | 2031 Value Projection: | US$ 2,562.1 Mn |
Canine influenza, commonly known as dog flu, is a contagious respiratory disease caused by influenza viruses that infect dogs. It is characterized by coughing, nasal discharge, and fever. While most dogs recover within 2-3 weeks, it can be fatal for young, old, or critically ill dogs. The global canine influenza vaccine market is driven by the growing cases of the virus across various regions. Increased awareness about the disease and availability of effective vaccination is supporting the market growth. However, lack of mandatory vaccination policies and high costs associated with vaccine production hampers the market potential. Overall, widespread R&D activities to develop new variants of the vaccine provide opportunities for market expansion in the coming years.
The global canine influenza vaccine market is witnessing a positive growth backed by the rising incidence of dog flu infections globally. As per research studies, the virus is widespread across North America, Asia Pacific, and several European countries. Growing dog ownership for companionship coupled with clustering of pets in kennels, dog shows, and parks aids in rapid transmission of the disease. This has boosted the demand for effective vaccination against canine influenza among pet owners and kennels. However, high capital investment required for vaccine production and lack of standard mass vaccination policies in some underdeveloped regions impedes the market growth. Moreover, constraints in supply chain disruptions due to the COVID-19 pandemic presented short-term challenges. Going forward, collaborative efforts from government agencies, vaccine developers, and veterinary practitioners to spread awareness about the illness and value of inoculation will create new opportunities.
Detailed Segmentation-